| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3847 | Nvp-sra880 | The first non-peptide somatostatin sst(1) receptor antagonist |
|
| DCC3848 | Nvp-tac544 | Novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R |
|
| DCC3849 | Nvp-vid400 | Specific inhibitor of the 25-hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase) |
|
| DCC3850 | Nvp-xaa228 | Novel potent PKCθ inhibitor |
|
| DCC3851 | Nvs-bet-2 | Novel selective bromodomain and extra-terminal domain (BET) protein family inhibitor (BETi ), inducing an ‘activated’ keratinocyte transcriptional profile with reversal of chronic wound biomarkers in human skin ex vivo |
|
| DCC3852 | Nvs-mllt-1 | Novel Potent and Selective inhibitor of YEATS proteins |
|
| DCC3853 | Nvs-pak1-c | Negative control for NVS-PAK1-1 (8778) |
|
| DCC3854 | Nvs-sm2 | Potent, orally active, small-molecule enhancer of SMN2 splicing, binding to and stabilizing the U1 snRNP:5′ss RNA complex |
|
| DCC3855 | Nvx-108 | Exceptional oxygen transporter, increasing brain tissue oxygen tension (PbtO2) when administered soon after traumatic brain injury (TBI) |
|
| DCC3856 | Nw-1772 | Highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor |
|
| DCC3857 | Nxd30001 | Novel potent Hsp90 inhibitor, inducing tumor regression in a genetically engineered mouse model of glioblastoma multiforme |
|
| DCC3858 | nxn-188 | Selective nNOS inhibitor and a5-HT1B/1D receptor agonist |
|
| DCC3859 | Nybomycin | Anti-microbial agent against Mycobacterium smegmatis and Mycobacterium bovis BCG, binding to DNA and inducing a unique morphological change to mycobacterial bacilli leading the bacterial cell death |
|
| DCC3860 | Ny-eso-1 | Cancer-testis antigen (CTA) with re-expression in numerous cancer types, eliciting spontaneous humoral and cellular immune responses, restricting expression pattern, being a good candidate target for cancer immunotherapy |
|
| DCC3861 | Nystatin-3 | Novel water-soluble nystatin derivative, being fully water-soluble (up to 1 g/mL) with the same potency of Nystatin but with 13.5 times lower toxicity |
|
| DCC3862 | O-1302 | Potent CB1 receptor antagonist |
|
| DCC3863 | O-1663 | Novel inhibitor of advanced stages of breast cancer, targeting multiple cannabinoid anti-tumour pathways |
|
| DCC3864 | o-1918 | Novel GPR18 antagonist, blocking the effects of Abn-CBD and NAGly. |
|
| DCC3865 | Oa-adp-hpd | Poly(ADP-Ribose) Glycohydrolase (PARG) inhibitor |
|
| DCC3866 | Oat-1441 | Novel Selective and Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase (hAMCase) |
|
| DCC3867 | O-bn-thaz Fumarate | Potent agonist of the human 5-HT2A and 5-HT2C receptors |
|
| DCC3868 | Obtusaquinone | Natural potent antineoplastic agent with promising in vivo activity in glioblastoma and breast cancer through the activation of oxidative stress |
|
| DCC3869 | Obtusilactone A | Inhibitor of mitochondrial Lon protease and activator of DNA damage checkpoints |
|
| DCC3870 | Obtusilactone B Featured | Specific inhibitor of vaccinia-related kinase 1 (VRK1)-mediated phosphorylation of barrier-to-autointegration factor (BAF) |
|
| DCC3871 | O-carbamate 66 | Novel potent antileishmanial and antitrypanosomal agent, offering a more optimal balance of increased solubility, suitable metabolic stability, excellent oral bioavailability (100%), and strong in vivo efficacy in a visceral leishmaniasis mouse model (97% |
|
| DCC3872 | Ocean Blue Se | Blue fluorescent labeling reagent |
|
| DCC3873 | Octamoxin | Irreversible and nonselective Monoamine_oxidase_inhibitor>monoamine oxidase inhibitor (MAOI) |
|
| DCC3874 | Octimibate | Potent non-prostanoid inhibitor of platelet aggregation, acting via the prostacyclin receptor |
|
| DCC3875 | Octreotideacetate GMP grade Featured | Agonist of sst2, sst3 and sst5 somatostatin receptors |
|
| DCC3876 | Ofh243 | Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist and weak inverse agonist |
|
